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Introduction
Nasopharyngeal carcinoma (NPC) is a human squamous cell cancer which is common in certain regions of southeastern Asia, including Taiwan and south China. It arises in the epithelium of the posterior nasopharynx and is primarily treated by radiotherapy. However, metastasis occurs in 7% of patients at the initial diagnosis and 20% or more develop metastasis after treatment. 1 This suggests that supplementary therapy is merited. Previous studies have indicated that Epstein-Barr virus (EBV) is closely associated with NPC, although viral gene expression is restricted in the tumor tissue. Only two virally encoded proteins, the EBV-encoded nuclear antigen 1 (EBNA1) and the latent membrane protein 1 (LMP1), have been detected in NPC biopsies by Western blot analysis. 2 Biologically, EBNA1 is an EBV-encoded transactivator and is required in trans to maintain the virus genome in an episomal form. 3 LMP1 is an integral membrane protein and has a profound effect on the morphology of rodent cells, indicating that the protein is potentially oncogenic. 4 LMP1 possesses the ability to transactivate the human immunodeficiency virus type 1 This activity is mainly induced by two domains within the C-terminal region of LMP1. [6] [7] [8] Therefore, both EBNA1 and LMP1 are important tumor-specific markers for NPC.
Recently, numerous reports have shown that successful transfer of the HSVtk gene renders cells sensitive to the antiviral agent ganciclovir (GCV). [9] [10] [11] [12] The HSVtk/GCV system has been shown to be effective in the treatment of transplanted tumors in animal models. [13] [14] [15] HSVtk converts GCV to a monophosphorylated form, which is then converted to a toxic triphosphate by cellular kinases. GCV-triphosphate then interferes with DNA synthesis, leading to cell death. 16, 17 In this study, we evaluated a strategy for the specific killing of the tumor cells by LMP1 activation of NF-B activity. To test this feasibility, expression of the HSVtk gene was placed under the control of the HIV LTR sequence which contained two copies of the NF-B motif. The introduction of this HIV LTRHSVtk cassette into LMP1-expressing cells resulted in a specific killing of HSVtk-expressing cells by GCV.
Results

LMP1-mediated transcriptional activation of NF-B
To examine the effect of LMP1 on NF-B activity, an epithelial tumor cell line, C33A, was cotransfected with LMP1-containing plasmid vectors (pT7(E) and p⌬94) and reporter plasmids (Figure 1) . The ␤-galactosidase activity was then assayed. As shown in Figure 2 , a 30-fold induction was observed in cells expressing LMP1 (p⌬94/pGN-LTR and pT7(E)/pGN-LTR). Mutations in the NF-B sequence abolished the activation (pT7(E)/pGN-mB and p⌬94/pGN-mB in Figure 2 ). This establishes clearly that the induction was specific via the NF-B binding motif and not of other sequences of the HIV-LTR sequence. On the other hand, no significant induction of the ␤-galactosidase activity was detected when cells were transfected with the vector DNA (pUC18/pGN-LTR and pUC18/pGN-mB). The induction was further examined in C33A cell clones that stably expressed LMP1 ( Figure  3b ). Using the activity from pGN-containing ⌬94 cells (Figure 3a , ⌬94/pGN) as the basal level, a 20-fold induction of the reporter gene activity by LMP1 was detected (Figure 3a , ⌬94/pGN-LTR). On the other hand, only a three-fold increase of activity was detected by LTR alone (Figure 3a , C33A/pGN-LTR). The activity in the parental C33A cells (data not shown) was similar to that of the ⌬94/pGN cells.
Thymidine kinase activity in HSVtk cell clones
In order to evaluate the HSVtk/GCV toxicity, stable cell clones were established which co-expressed both LMP1 and HSVtk. As shown in Figure 4 , a three-to four-fold induction of thymidine kinase activity was demonstrated in four individual cell clones (⌬94/pLTR-tk 4, 5, 6 and 7) and compared to the TK activity in the stable cell clone that only expressed HSVtk (C33A/pLTR-tk). The stable cell clone expressing LMP1 (⌬94) or the parental cells (C33A) showed only a basal level of thymidine kinase activity which was approximately one half of the activity demonstrated in C33A/pLTR-tk cell clone.
In vitro GCV sensitivity tests of LMP1-and HSVtkexpressing cell clones To examine if LMP1 and HSVtk-positive cell clones were sensitive to GCV treatment in cultured cells, cells of each clone (10 4 ) were plated in either a regular medium or a medium supplemented with a range of concentrations of ganciclovir. The surviving cells were counted 4 days later ( Figure 5 ). At 50 g/ml of GCV, approximately 40% of LMP1-and HSVtk-positive cells were killed and at 200 g/ml, more than 50% of cells were killed. At 300 g/ml of GCV, approximately 10% of cells survived. At higher doses (500 or 1000 g/ml), there were almost no surviving cells despite simultaneous killing of HSVtk DNA-free cells (C33A and ⌬94). In contrast, more than 90% of parental C33A cells, C33A cells expressing LMP1 gene only (⌬94) or cells expressing HSVtk gene (C33A/pLTR-tk), survived at lower doses (10 and 50 g/ml) and 50% cell survival was still detected at 500 g/ml of GCV. These data indicate that cells carrying both LMP1-and HSVtk genes were highly sensitive to GCV treatment.
In vivo effect of GCV on tumor mass derived from LMP1-and HSVtk-expressing cell clones To examine if the LMP1-and HSVtk-positive cell clones were also GCV-sensitive in vivo, 5 × 10 6 tumor cells were inoculated s.c. at the flank of nude mice and the mice were then treated with GCV. Palpable tumors appeared within 14 days after the initial inoculation. The mice were then injected daily with GCV (100 mg/kg body weight) for 7 days. As shown in Figure 6a , the growth of tumors was suppressed due to GCV treatment only in tumors derived from LMP1-and HSVtk-expresssing cells (C33A/⌬94/pLTR-tk 5 and tk 6), but not from C33A cells expressing only LMP1 (⌬94) or HSVtk (C33A/pLTR-tk). Similar results were also observed for tumors derived from the C33A/⌬94/pLTR-tk 4 and tk 7 cell clones (data not shown). During the study period, no apparent body weight loss was observed in mice treated with GCV.
To monitor tumor progression and the effect of GCV treatment, the diameter of tumors was measured every 2 or 3 days. In this study, mice were divided into eight groups. Mice in group 1 were inoculated with C33A/pLTR-tk cells and treated with 0.9% NaCl solution; mice in group 2 were inoculated with C33A/pLTRtk cells and treated with GCV; mice in group 3 were inoculated with ⌬94 cells and treated with 0.9% NaCl solution; mice in group 4 were inoculated with ⌬94 cells and treated with GCV; mice in group 5 were inoculated with ⌬94/pLTR-tk 5 cells and treated with 0.9% NaCl solution; mice in group 6 were inoculated with ⌬94/pLTR-tk 5 cells and treated with GCV; mice in group 7 were inoculated with ⌬94/pLTR-tk 6 cells and treated with 0.9% NaCl solution; and mice in group 8 were inoculated with ⌬94/pLTR-tk 6 cells and treated with GCV. As shown in Figure 6b , the animals remained tumor-free only if the tumors were derived from cell clones that stably expressed both the LMP1 and the HSVtk genes (⌬94/pLTR-tk 5) and with GCV treatment. The regression did not occur during the period (7 days) of GCV treatment but 7 days after the termination of the GCV regimen. The regression was progressive for 9 days until no apparent tumor mass was visible and such an apparent complete regressed stage was maintained for at least 12 days (days 30-42). Tumor mass reappeared approximately 20 days after the termination of GCV treatment (on day 42). Similar results were obtained with the cell clone ⌬94/pLTR-tk 6. Tumors derived from cells stably expressing the HSVtk gene showed a slight regression of tumor load 9 days after completion of the GCV treatment. These tumors regained their growth after 12 days, but at a moderate rate under GCV treatment, suggesting a mild antitumor effect. For example, the average diameter of the tumors was 0.6 cm on day 40 and measured 1.15 cm on day 49, as compared with a growth from an average of 1.1 cm to 1.63 cm with no GCV treatment (C33A/pLTR-tk). The tumor growth pattern (data not shown) for LMP1-expressing cell clone (⌬94) or the parental C33A cells in GCV-and salinetreated groups was similar to untreated C33A/pLTR-tk and ⌬94/pLTR-tk 5 cell clones (Figure 6b ). Without the GCV treatment, tumors derived from cells stably expressing LMP1-and HSVtk genes (⌬94/pLTR-tk5), from cells stably expressing HSVtk gene (C33A/pLTR-tk), or from the parental C33A cells (data not shown) showed no retardation of growth. Some animals died before the end of the observation period (70 days) due to the extensive size of the tumor mass.
Discussion
Tumor-specific killing using the HSVtk/GCV system has been demonstrated in a number of solid tumors when a tumor-specific protein can be identified. Such examples have been demonstrated in the cases of specific expression of the ␣-fetoprotein promoter in hepatoma, 18 the tyrosinase promoter in melanoma, 19 the carcinoembryonic antigen promoter in adeno-carcinoma 10 and the Myc-Max response elements in small cell lung cancer. 15 In these cases, a HSVtk gene under the transcriptional regulation of the promoter sequences of these genes is activated specifically in tumor cells. A similar strategy has recently been proposed for treatment of EBV-associated malignancies using the transactivating effect of EBNA1 on a stretch of 30-bp repeats (family of repeats, FR) located near the oriP region of the EBV genome. [20] [21] [22] In this study, we report the feasibility of another strategy which takes advantage of the regular expression of the EBV transforming protein, LMP1, in NPC cells versus normal cells and the fact that LMP1 is a transcriptional transactivator of the NF-B motif. 5 The NF-B activity is then used to enhance the expression of the therapeutic gene, the HSVtk gene. Upon treatment with GCV, only those LMP1-positive cells activate the HSVtk gene expression and are then selectively killed. We demonstrated that elevated expression of the HSVtk gene could be induced by LMP1 transactivation through the NF-B binding motif located within the HIV-LTR sequence. The presence of LMP1 has led to a marked increase in chemosensitivity to GCV in transfected cells. Tumors derived from such cell clones in nude mice were similarly sensitive to GCV as shown by the elimination of tumor burdens in GCV-treated animals. Persistent growth of tumor loads in control (saline-treated) animals demonstrates that insertion of the exogenous DNA into the cellular genome had little impact on the malignant capacity of tumor cells. The differences observed in tumor regression between GCV-treated or untreated tumor contents suggest clearly that the expression of the LMP1 gene was mainly responsible for the observed enhanced HSVtk/GCV killing of the tumor cells.
Figure 1 Construction of plasmids used in this study. Expression of the LacZ gene of pGN-LTR was regulated by HIV-LTR. Plasmid pGN-mB was derived from pGN-LTR and contained mutations at the NF-B binding sites within the LTR. The HSVtk gene was under the control of HIV-LTR in pLTR-tk (see Materials and methods for details).
Figure 2 Activation of NF-B activity by LMP1 in transient transfection experiments. LMP1-expressing plasmids (pT7(E) and p⌬94) and reporter plasmids were cotransfected into C33A cells and the ␤-galactosidase activity was determined. Reporter plasmid pGN-LTR contained the HIV-LTR fragment and pGN-mB contained mutations at the NF-B binding sites of HIV-LTR. Plasmid pUC18 was used as the vector control for the effector plasmids, pT7(E) and p⌬94. pGN was a promoterless plasmid and used as a negative control for the reporter plasmids. Plasmid pCMV-LacZ contained a ␤-galactosidase gene under the control of CMV-IE promoter. Introduction of this plasmid into cells was used as a monitor for transfection efficiency. Data were the average of at least six independent transfection experiments in duplicates. The standard deviation is indicated by the horizontal bars.
Figure 3 Activation of NF-B activity in
One may be concerned if the level of LMP1 protein expressed in these stable cell clones were compatible with that from the individual NPC biopsy. Using Western blot analysis and LMP1-specific S12 monoclonal antibody, we found that the LMP1 protein in the stable cell clones was similar to the level detected in NPC biopsies (data not shown). Therefore, the effect on activation of NF-B activity by LMP1 shown in the in vivo animal study ( Figure 6 ) may be equally efficient in the natural NPC biopsies. The LMP1 expression in the neoplastic cells of other EBV-associated tumors such as Hodgkin's disease 23 and B cell lymphoma in the immunocompromised patients 24 have been confirmed by the immunostaining analysis with LMP1-specific monoclonal antibodies. Judging from the intensity of staining, the level of LMP1 expression in the above tumors was similar to or stronger than that detected in tumor cells of NPC biopsies. The expression of LMP1 in T cell lymphoma has been demonstrated by RT-PCR and immunostaining. 25 However, it appears to be restricted to a minor population of large or giant lymphoid cells in nasal T cell lymphoma and angioimmunoblastic lymphoadenopathy (AILD)-like T cell lymphoma. Further evaluation of the variability of LMP1 expression in these tumors is required before the application of this therapeutic strategy.
The C-terminal region of LMP1 is where the transactivator function lies in the protein. In NPC biopsies and lymphoid neoplasia, this region carries a typical 30-bp deletion and other sequence changes, as compared with the corresponding region of LMP1 derived from that reported in a B cell line, B95-8. 4, 26, 27 Mutational studies using chimeric proteins between these two types of LMP1 or truncated proteins showed that the variations have no effect on the activation of NF-B activity. 28, 29 Therefore, the natural variations which existed in LMP1 in various EBV-associated tumors should not affect the gene therapy strategy proposed in this study.
For NPC cells, both EBNA1 and LMP1 are considered to be important molecular markers. Expression of these two genes in NPC and in lymphoblastoid cell lines (LCLs) is achieved using different sets of promoter sequences. EBNA1 is directed from promoter Qp, which is located at the BamHI Q fragment of the EBV genome, 30 and transcription of the LMP1 gene is preferentially directed from promoter ED-L1E, 31 located approximately 500 bp upstream from the putative promoter ED-L1. Sequence analysis of the upstream region of these promoters has indicated that they lack the NF-B binding motif. It may, therefore, be possible to incorporate multiple copies of the NF-B binding motif into the promoter sequences of these genes to achieve a higher level of NPC-specific transcriptional regulation of therapeutic genes, such as the HSVtk gene. This will result in a further enhanced expression of HSVtk gene from a NPCspecific promoter (Chang YS, unpublished data). Tumor cells expressing higher levels of HSVtk gene can presumably be killed more efficiently at lower doses of GCV. However, more studies are needed to prove the usefulness or feasibility of this modification.
Our strategy was tested using a tumor cell line that specifically expressed the NPC marker (LMP1) and the HSVtk gene. Although the data presented appear promising, there are potential problems that need to be resolved before the clinical application to NPC treatment. For example, in vivo delivery of the therapeutic gene to the NPC cells remains uncertain. Currently, many therapeutic genes are delivered by recombinant adenoviral and retroviral infections or by a direct liposomemediated introduction of plasmid vectors. 11, 12 For tumors of epithelial cell origin like NPC, the adenovirus approach or the liposome-mediated delivery system may be tested because both methods are relatively safe to use and the efficient delivery of therapeutic genes to the target sites has been reported. Another potential drawback for this strategy is due to the nature of NPC. More than 50% of tumors expressed LMP1 that is at a level detectable by Western blot analysis 2 and another 30-40% of tumors contained LMP1 transcripts that can only be detected by the RT-PCR method with LMP1-specific primer set (Chang YS, unpublished data). Furthermore, it is common in NPC that only a fraction of tumor cells will express LMP1 as examined by the immunocytostaining analysis using LMP1-specific antibodies (data not shown). However, because the 'bystander effect' of the HSVtk/GCV 'prodrug' system is an important feature and has been reported to play a central role in tumor eradication, this problem may be circumvented. For NPC that expressed no or a low level of LMP1, introduction of both LMP1 gene and HSVtk gene to the tumor cells may be required for sufficient killing by GCV.
In this study, we observed a gradual redevelopment of tumors in the mice upon cessation of GCV treatment, as previously reported by other investigators. 10, 32 It has been suggested that a small number of tumor cells may have escaped the cell cycle control during GCV treatment. On cessation of GCV treatment, the surviving tumor cells reenter the cell cycle and develop into new tumor masses. 32 These recurrent tumor cells may be resistant to GCV despite retaining a functional HSVtk gene. 10 To prevent tumor redevelopment, early and/or multiple GCV treatment, or GCV treatment in combination with radiation therapy to destroy the escaped tumor cells further, are a few potential protocols that may be explored using the mouse model system described in this report.
In summary, the LMP1-regulated therapeutic gene expression system demonstrated in this study provides a basis for further development of a novel targeted gene therapeutic treatment of NPC and other EBV-associated and LMP1-positive malignancies such as T cell lymphoma, Hodgkin's disease and B cell lymphoma in immunocompromised patients.
Materials and methods
Cell lines C33A is a human cervical carcinoma cell line (ATCC, Rockville, MD, USA). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (GIBCO, Grand Island, NY, USA).
Plasmid construction
Plasmid pGN was constructed by insertion of a 3.5 kb NotI-NotI fragment (containing the LacZ gene) from pNASS␤ (Clontech, Palo Alto, CA, USA) into the SmaI site of the plasmid pGEM-7Zf(−) (Promega, Madison, WI, USA). The 800 bp HIV-LTR fragment was excised from the plasmid pC15 with XbaI and HindIII and inserted into the Csp45I site of pGN. The resulting plasmid was designated as pGN-LTR. To generate mutated NF-B motifcontaining plasmid, overlapping extension PCR and two sequence-specific mutagenized primers were used. The primers with the mutated NF-B sequence were 5Ј-CAATCTACTTTCCGCTGTCTAC-3Ј (lcy1) and 5Ј-GTA-GACAGCGGAAAGTAGATTG-3Ј (yeh2). The primer lcy1 was designed to contain specific mutations (GGG to TCT) in both copies of the NF-B-binding sites as previously described. 5 The sequence of yeh2 was complementary to lcy1. The other two primers were 5Ј-AATTCGAACGAGCTGAGCCAGCAG-3Ј (yeh 1, −680 to −662 of LTR) and 5Ј-AGTTCGAAGGCAAGCTTT ATTGAGGC-3Ј (yeh 3, +88 to +69). A DNA fragment of 602 bp was generated with yeh1 and yeh2 and a DNA fragment of 201 bp was generated with lcy1 and yeh3. These two fragments were subjected to an overlapping extension PCR by 10 cycles of denaturation at 95°C for 1 min, annealing at 45°C for 2 min and extension at 72°C for 3 min, followed by 36 cycles of denaturation at 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. The final PCR product was 781 bp in length and was inserted into the Csp45I site of pGN. The resulting plasmid was designated as pGN-mB. For the HSVtk/GCV assay, the full length LacZ gene of pGN-LTR was removed by digestion with SmaI/EcoRI and replaced with a 1476-bp fragment containing the HSVtk gene excised from BglII/NcoItreated pHSV-106 (GIBCO). This plasmid was designated as pLTR-tk (Figure 1) .
Plasmid pCMV-LacZ was generated by placing the LacZ gene under the control of cytomegalovirus IE gene promoter. This plasmid DNA was used as a transfection control in the transient transfection experiments.
The LMP1 gene-containing plasmid, pT7(E), was derived from a genomic clone 1510 of a NPC-derived library. 4 Plasmid p⌬94 was obtained by deletion of a 94-bp fragment, which was the putative promoter of the LMP1 gene. In this construct, the expression of LMP1 gene was directed from an upstream promoter, ED-L1E. 31 
DNA transfection
Plasmid DNA was amplified in Escherichia coli and was purified by two sequential cesium chloride gradients. For DNA transfection, 1 × 10 6 C33A cells in six-well culture plates were transfected with 5 g of plasmid DNA by the calcium phosphate precipitation method as described previously. 33 Cells were then harvested 24 h after transfection and were examined by the ␤-galactosidase activity assay described below.
⌬94 is a C33A cell clone that contained p⌬94 and stably expressed LMP1. 31 These cells were grown in culture medium containing 500 g/ml of G418.
For the establishment of LMP1-positive cell clones that also expressed the HSVtk gene, ⌬94 cells were cotransfected with 0.5 g of pBabe-Hygro (replacement of the puromycin gene of pBabe-puro with the hygromycin gene) and 10 g of pLTR-tk DNA. Cells were selected for their resistance to both G418 and hygromycin B. These cells were maintained in DMEM medium containing 10% FBS, 500 g/ml of G418 and 200 g/ml of hygromycin B.
␤-Galactosidase activity assay C33A or ⌬94 cells (1 × 10 6 ) seeded in six-well plates were transfected with various reporter constructs described above. After 24 h, the ␤-galactosidase activity was assayed by the ␤-galactosidase enzyme assay system with reporter buffer according to the manufacturer's instructions (Promega).
Thymidine kinase activity assay Nearly confluent cultures of C33A, C33A/pLTR-tk, ⌬94 and ⌬94/pLTR-tk cells were harvested and pelleted by centrifugation at 200 g for 5 min at 4°C. Cells were suspended in 200 l of lysis buffer (10 mm Tris-Cl; pH 7.5, 10 mm KCl, 2 mm MgCl 2 , 1 mm ATP, 10 mm NaF, 0.5% NP-40 and 10% glycerol) and lysed by repeated pipetting. Cell lysates were clarified by centrifugation at 12 000 g for 5 min. Ten microliters (25 g) of each cell lysate were mixed with 75 l of a reaction mixture containing 0.16 m Tris-Cl (pH 7.5), 0.14 mm albumin, 12.6 mm creatine phosphate, 11.2 U/ml creatine phosphokinase, 10 m 3 Hthymidine (sp act 6.7 Ci/mmol), 2 mm ATP, 2 mm MgCl 2 , 7.5 mm NaF and 1.6 mm DTT. The mixture was incubated at 37 o C for 30 min. A 50 l sample was spotted on to a Whatman DE-81 filter, washed twice with 95% alcohol and dried. The radioactivity on the filters was measured by a liquid scintillation counter LS-500OTD (Beckman, Fullerton, CA, USA).
GCV sensitivity assay in cultured cells
In cell survival assays, cells were plated into 96-well microplates with a density of 10 4 cells per well. After 18 h, the regular medium was replaced with fresh medium containing ganciclovir at a range of concentrations up to 1000 g/ml in duplicates. After 4 days, the percentage of cell survival was determined using the Cell Titer 96 AQ UEOUS Non-Radioactive Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. The absorption of cells in each well was measured by a MR5000 microwell plate reader (DYNATCH Laboratories, Chantilly, VA, USA) at 490 nm. The percentage of cell survival was calculated using the following equation: % survival cell = (absorption of GCV-treated cells/absorption of control cells) × 100%.
In vivo GCV sensitivity study using nude mice model Female BALB/c-nu/nu 6-week-old mice were used to test the effect of GCV in vivo. Cells (5 × 10 6 ) were suspended in 200 l of phosphate-buffered saline and were injected subcutaneously in the flank of nude mice. GCV (100 mg/kg) in 200 l 0.9% NaCl solution was injected once daily to mice intraperitoneally for 7 days when tumors became palpable (14 days after tumor inoculation). Diameter of tumors was measured at 3-day intervals.
